IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 2, January 2026
Impact Factor: 7.67

A Review on Drug Safety and Pharmacovigilance

[1*]Aarti R. Santre, [1]Parmeshwar B. Matlabe, [1]Shital Pawar, [1]Vaibhav P. Raut
[1]Raosaheb Patil Danve College of Pharmacy, Badnapur
Dr. Babasaheb Ambedkar Technological University, Lonere, Raigad MS
Corresponding Author: Aarti R. Santre
rukhamansantre@gmail.com

Abstract: *Drug safety and pharmacovigilance are fundamental to ensuring the safe and effective use of pharmaceutical products. This review presents a comprehensive overview of current drug safety and pharmacovigilance practices, highlighting advancements in surveillance systems such as spontaneous reporting mechanisms and signal detection methodologies. Despite notable progress, persistent challenges including underreporting of adverse drug reactions (ADRs), data quality limitations, and regulatory disparities across regions continue to affect the effectiveness of pharmacovigilance systems. The review emphasizes the importance of collaborative efforts among regulatory authorities, healthcare professionals, pharmaceutical industries, and patients. Strategies for improvement include education and awareness initiatives, strengthening surveillance infrastructure, regulatory convergence, integration of advanced technologies such as artificial intelligence, and adoption of patient-centered approaches. Effective pharmacovigilance remains essential for maintaining public trust and ensuring the safety of pharmaceutical interventions worldwide.*

Keywords: Pharmacovigilance, Adverse Drug Reactions, Drug Safety, WHO, Reporting Systems, Signal Detection

I. INTRODUCTION

Ensuring the safety and efficacy of pharmaceutical products is a cornerstone of modern healthcare. Pharmacovigilance, defined as the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems, plays a critical role in safeguarding public health. Over the years, pharmacovigilance practices have evolved in response to advancements in medical science, regulatory requirements, and a growing emphasis on patient-centered care.

Pharmacovigilance systems rely on collaboration among regulatory agencies, pharmaceutical manufacturers, healthcare professionals, and patients to collect and analyze data on ADRs. While substantial progress has been made in developing sophisticated reporting systems and regulatory frameworks, challenges such as underreporting, variability in data quality, and regulatory heterogeneity remain. These issues highlight the need for continuous innovation and coordinated global efforts to strengthen pharmacovigilance systems and improve patient outcomes.

OVERVIEW OF PHARMACOVIGILANCE SYSTEMS

Modern pharmacovigilance systems are designed to monitor drug safety throughout the product lifecycle. Spontaneous reporting systems, post-marketing surveillance studies, and risk management plans form the backbone of global drug safety monitoring. Electronic health records, real-world evidence, and international databases such as VigiFlow and VigiBase support the systematic collection and evaluation of safety data.

The information flow typically begins with healthcare professionals or patients observing suspected ADRs, which are then reported to national pharmacovigilance centers. These reports are analyzed, coded using standardized terminologies, and transmitted to global databases for signal detection and assessment. This interconnected framework enables the identification of potential safety concerns and supports timely regulatory decision-making.

DOI: 10.48175/568

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 2, January 2026 Impact Factor: 7.67

ADVANCEMENTS IN DRUG SAFETY AND PHARMACOVIGILANCE

Significant advancements have been achieved in drug safety monitoring over recent decades. The establishment of spontaneous reporting systems and international pharmacovigilance networks has improved the detection and assessment of ADRs. Signal detection methodologies, including statistical data mining and disproportionality analysis, have enhanced the ability to identify potential safety signals from large datasets.Risk management plans and post-marketing surveillance studies provide structured approaches to monitor drug safety beyond clinical trials. The integration of real-world evidence from electronic health records, claims databases, and patient registries has further enriched pharmacovigilance activities by offering insights into drug utilization patterns and outcomes in diverse populations. Additionally, digital health technologies such as mobile applications and wearable devices are increasingly contributing to real-time safety monitoring and patient engagement.

CHALLENGES AND CRITICISMS IN PHARMACOVIGILANCE

Despite these advancements, pharmacovigilance systems face several limitations. Underreporting of ADRs remains a major concern, often due to lack of awareness, time constraints, and perceived reporting burdens among healthcare professionals. Variability in data quality and inconsistencies in reporting formats hinder effective data analysis and interoperability.

Regulatory disparities across countries complicate global pharmacovigilance efforts, leading to inefficiencies in information sharing and risk management. Furthermore, while emerging technologies such as artificial intelligence and machine learning offer promising opportunities for enhanced signal detection, their integration raises ethical, legal, and technical challenges that require careful consideration.

ROLE OF EMERGING TECHNOLOGIES AND PATIENT-CENTERED APPROACHES

The adoption of advanced technologies has the potential to transform pharmacovigilance practices. Artificial intelligence, machine learning, and natural language processing can improve signal detection, predictive modeling, and risk assessment. Big data analytics enables efficient processing of large volumes of safety data, supporting proactive risk management.

Patient-centered pharmacovigilance approaches emphasize the active involvement of patients in reporting and monitoring ADRs. Patient-reported outcomes provide valuable insights into real-world medication experiences, fostering transparency and enhancing the relevance of safety data. Engaging patients as key stakeholders strengthens trust and accountability within pharmacovigilance systems.

FUTURE SCOPE

To address existing gaps and enhance pharmacovigilance effectiveness, several strategic recommendations are proposed:

- **Education and Awareness:** Strengthening educational initiatives for healthcare professionals and patients to promote proactive ADR reporting.
- **Enhanced Surveillance Infrastructure:** Investing in interoperable digital platforms and robust data management systems.
- **Regulatory Convergence:** Harmonizing pharmacovigilance standards and reporting requirements globally.
- **Integration of Advanced Technologies:** Leveraging artificial intelligence and big data analytics for improved signal detection and risk mitigation.
- **Patient-Centered Pharmacovigilance:** Actively involving patients in safety monitoring and decision-making processes.
- **Proactive Risk Communication:** Ensuring timely, transparent dissemination of drug safety information to all stakeholders.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 2, January 2026 Impact Factor: 7.67

No.	Paper Title	Journal/ Source	Author(s)	Year	Key Conclusion
1	Post-marketing safety surveillance of atezolizumab based on FAERS	*Scientific Reports*	Zhang, G. et al.	2025	Retrospective FAERS analysis revealed safety signals and ADR patterns for atezolizumab, illustrating the value of large SRS databases in post-marketing pharmacovigilance.
2	Serious adverse drug reactions associated with anti-SARS-CoV-2 vaccines	*Scientific Reports*	Nazar, W. et al.	2025	Analysis of EudraVigilance data identified serious ADR reporting trends for COVID-19 vaccines, showing pharmacovigilance relevance during public health interventions.
3	A Data-Driven Reference Standard for ADR Signal Assessment (RS-ADR)	*Journal of Medical Internet Research*	Juhn et al.	2022	Developed a comprehensive real-world data reference set (RS-ADR) that enhances systematic ADR signal detection and validation in pharmacovigilance.
4	A Comparison of Active Pharmacovigilance Strategies Used to Monitor Adverse Events to Antiviral Agents	*Drug Safety*	Ferreira-da-Silva, R. et al.	2024	Systematic comparison of active pharmacovigilance methods showed varied effectiveness across antiviral ADR monitoring strategies, highlighting methodological choices in surveillance.
5	Long-term trends in reporting of cardiac ADRs to COVID-19 vaccines	*BMC Infectious Diseases*	Nazar, W. et al.	2025	Explored reporting trends in vaccine-related cardiac ADRs, emphasizing long-term data analysis and signal patterns in spontaneous reporting systems.
6	Spontaneous ADRs in a thirteen-year pharmacovigilance program	*Frontiers in Pharmacology*	Montané et al.	2024	Longitudinal hospital pharmacovigilance data highlighted real-world ADR reporting dynamics and the importance of institutional PV programs.
7	Potential for detection of safety signals for OTC medicines using national ADR data	*Pharmacy (MDPI)*	Chimano K. et al.	2020	Demonstrated that spontaneous national ADR reporting can detect safety signals for over-the-counter drugs, reinforcing the role of surveillance data in public health safety.

II. RESULT AND DISCUSSION

The analysis of recent literature highlights significant progress in drug safety monitoring and pharmacovigilance practices across diverse therapeutic areas. Studies based on large spontaneous reporting system (SRS) databases such as FAERS and EudraVigilance demonstrate the effectiveness of post-marketing surveillance in identifying adverse drug reaction (ADR) patterns and safety signals. Recent investigations involving anticancer agents and COVID-19 vaccines revealed clinically relevant safety signals, emphasizing the importance of continuous monitoring during widespread drug utilization.

Comparative evaluations of active pharmacovigilance strategies indicate variability in effectiveness depending on study design, therapeutic class, and data source. Hospital-based and institutional pharmacovigilance programs showed improved ADR reporting rates and long-term trend analysis capabilities. The integration of real-world evidence (RWE), including electronic health records and patient registries, contributed to enhanced understanding of drug utilization patterns and long-term safety outcomes.Data-driven methodologies, including standardized reference sets for signal assessment, improved the accuracy and validation of detected ADR signals. Studies focusing on over-the-counter

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 2, January 2026 Impact Factor: 7.67

(OTC) medicines confirmed that national ADR databases are capable of identifying meaningful safety concerns, reinforcing the value of spontaneous reporting systems in public health protection. Overall, the reviewed evidence confirms that pharmacovigilance systems are increasingly effective but remain influenced by reporting quality, infrastructure strength, and regulatory consistency.

The findings from the reviewed studies align with the core objectives of pharmacovigilance—early detection, assessment, and prevention of adverse drug reactions to ensure patient safety. Advances in spontaneous reporting systems and international databases have significantly strengthened global drug safety surveillance. The successful detection of safety signals in post-marketing studies highlights the critical role of pharmacovigilance beyond pre-clinical and clinical trial phases.

However, underreporting remains a persistent limitation, particularly among healthcare professionals, due to lack of awareness, time constraints, and perceived complexity of reporting systems. Variability in data quality and reporting formats further complicates signal detection and cross-country comparisons. These challenges emphasize the need for standardized reporting frameworks and regulatory convergence.The growing application of artificial intelligence, machine learning, and big data analytics represents a transformative shift in pharmacovigilance practices. These technologies enhance signal detection efficiency, predictive risk modeling, and large-scale data analysis. Nevertheless, ethical considerations, data privacy concerns, and technical integration issues must be addressed to ensure responsible implementation.Patient-centered pharmacovigilance emerged as a key theme across the literature. Active patient involvement through patient-reported outcomes improves transparency, enriches safety data, and fosters trust in healthcare systems. The reviewed studies collectively support the integration of technological innovation, regulatory harmonization, and patient engagement as essential components for strengthening pharmacovigilance frameworks.

III. CONCLUSION

This review underscores the critical role of pharmacovigilance in safeguarding public health and ensuring the safe and effective use of pharmaceutical products. Evidence from recent studies demonstrates substantial progress in drug safety monitoring through advanced surveillance systems, real-world data integration, and international collaboration. Post-marketing surveillance and spontaneous reporting systems remain indispensable tools for identifying and managing adverse drug reactions.

Despite these advancements, ongoing challenges such as underreporting, data quality limitations, and regulatory disparities continue to affect pharmacovigilance effectiveness. Addressing these challenges requires sustained efforts in education, infrastructure development, regulatory convergence, and adoption of advanced analytical technologies. Furthermore, incorporating patient-centered approaches enhances data relevance and strengthens public trust.In conclusion, the future of pharmacovigilance depends on a balanced integration of innovation, collaboration, and patient engagement. Strengthened pharmacovigilance systems will not only mitigate drug-related risks but also promote transparency, accountability, and confidence in healthcare systems worldwide, ultimately contributing to improved patient outcomes and public health protection.

REFERENCES

[1]. Li Y, Wu Y, Jiang T, Xing H, Xu J, Li C, Liu Y.Opportunities and challenges of pharmacovigilance in special populations: A narrative review of the literature. *Therapeutic Advances in Drug Safety.*2023;14:20420986231200746.

[2]. Thomas F, Abiri OT, Komeh JP, Conteh TA, Bah AJ, Kanu JS, Terry R, Abrahamyan A, Thekkur P, Zachariah R.Inconsistent country-wide reporting of adverse drug reactions to antimicrobials in Sierra Leone (2017–2021): A wake-up call to improve reporting. *International Journal of Environmental Research and Public Health.*2022;19:3264.

[3]. Salehi T, Seyedfatemi N, Mirzaee MS, Maleki M, Mardani A.Nurses' knowledge, attitudes, and practice in relation to pharmacovigilance and adverse drug reaction reporting: A systematic review. *BioMed Research International.*2021;2021:1–12.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 2, January 2026
Impact Factor: 7.67

[4]. Kopciuch D, Zaprutko T, Paczkowska A, Ratajczak P, Zielińska-Tomczak Ł, Kuś K, Nowakowska E.Safety of medicines—Pharmacists' knowledge, practice, and attitudes toward pharmacovigilance and adverse drug reaction reporting process. *Pharmacoepidemiology and Drug Safety.*2019;28(12):1543–1551.

[5]. Kengar MD, Patole KK, Ade AK, Kumbhar SM, Patil CD, Ganjave AR. Introduction to pharmacovigilance and monitoring.*Asian Journal of Pharmaceutical esearch.*2019;9(2):116–122.

[6]. DeFrank JT, McCormack L, West SL, Lefebvre C, Burrus O.Unintended effects of communicating about drug safety issues: A critical review of the literature.*Drug Safety.*2019;42(10):1125–1134.

[7]. Beninger P. Pharmacovigilance: An overview. *Clinical Therapeutics.*2018;40(12):1991–2004.

[8]. Price J.Pharmacovigilance in crisis: Drug safety at a crossroads. *Clinical Therapeutics.*2018;40(5):790–797.

[9]. Palaian S.Pharmacovigilance practices and activities: Issues, challenges, and future direction. In: *Social and Administrative Aspects of Pharmacy in Low- and Middle-Income Countries.* Academic Press; 2018. p. 145–162.

[10]. Hadi MA, Neoh CF, Zin RM, Elrggal ME, Cheema E.Pharmacovigilance: Pharmacists' perspective on spontaneous adverse drug reaction reporting. *Integrated Pharmacy Research and Practice.*2017;6:91–98.

[11]. Laporte JR. Fifty years of pharmacovigilance—medicines safety and public health. *Pharmacoepidemiology and Drug Safety.*2016;25(6):725–732.

[12]. Bhagavathula AS, Elnour AA, Jamshed SQ, Shehab A.Health professionals' knowledge, attitudes and practices about pharmacovigilance in India: A systematic review and meta-analysis. *PLOS One.*2016;11(3):e0152221.

[13]. Sportiello L, Rafaniello C, Scavone C, Vitale C, Rossi F, Capuano A. The importance of pharmacovigilance for drug safety: Focus on cardiovascular profile ofincretin-based therapy. *International Journal of Cardiology.*2016;202:731–735.

[14]. Smith MY, Benattia I.The patient's voice in pharmacovigilance: Pragmatic approaches to building a patient-centric drug safety organization. *Drug Safety.*2016;39:779–785.

[15]. Da Pan GJ.Ongoing challenges in pharmacovigilance. *Drug Safety.*2014;37:1–8.

[16]. Abubakar AR, Simbak NB, Haque M.A systematic review of knowledge, attitude and practice on adverse drug reactions and pharmacovigilance among doctors. *Journal of Applied Pharmaceutical Science.*2014;4(10):117–127.

[17]. Jeetu G, Anusha G.Pharmacovigilance: A worldwide master key for drug safety monitoring. *Journal of Young Pharmacists.*2010;2(3):315–320.

[18]. Härmark L, Van Grootheest AC.Pharmacovigilance: Methods, recent developments and future perspectives. *European Journal of Clinical Pharmacology.*2008;64:743–752.

[19]. Nelson RC, Palsulich B, Gogolak V.Good pharmacovigilance practices: Technology enabled. *Drug Safety.*2002;25:407–414